FDA clears 1st Direct to Consumer genetic test to predict Al
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The US Food and Drug Administration (FDA) has allowed 23andMe, a genetic testing company, to market its "controversial" direct-to-consumer tests for assessing the risk for 10 diseases or conditions, including Alzheimers and Parkinsons disease.

These are the first direct-to-consumer tests authorised by the FDA that provide information on an individual's genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional.

http://www.business-standard.com/article/current-affairs/fda-clears-genetic-test-to-predict-alzheimer-s-parkinson-s-diseases-117040800457_1.html
Preview
Like
Comment
Share